E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Osteoarthrosis of the knee and hip. - Clinical symptoms due to osteoarthrosis of the knee and hip consisting of pain, stiffness and functional restriction. |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Study of the effectiveness of treatment with chinese herbal remedies in form of decoction prescribed according to the diagnostic paradigma of traditional chinese medicine.
Primary scientific question: is there a difference in the efficacy of herbal remedies in the osteoarthrosis of knee and hip wether they are prescribed according to the diagnostic rules of traditional chinese medicine or in a more or less by chance way of prescription?
Null hypothesis: there is no difference in efficacy of herbal prescriptions, no matter if diagnostic aspects according to TCM underly the their prescription or not.
|
|
E.2.2 | Secondary objectives of the trial |
-Observations concerning the therapeutic spectrum of the employed herbal remedies. -Questions concerning the safety and digestibility of the employed herbal remedies. -Questions of how general life quality is influenced by this kind of regime ( life quality is also a secondary evaluation parameter) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- age: 45-70years - validated diagnosis of osteoarthrosis of knee or hip - result of 30-75mm in VAS in first screening - result of 30-75mm im Global WOMAC score in entry- examination - compliance for procedure of ingesting herbal decoctions and blood-testing. - everday mobility, patient should be able to walk. |
|
E.4 | Principal exclusion criteria |
- operations in the affected joint - arthroscopic interventions in the affectec joint one year before the start of trial - intraarticular injektion of cortisone or systemic application of cortisone during 8 weeks before start of trial. - inflammatory rheumatic disease of joint, ESR > 40mm/h - Hip pain, which is due to congenital joint dysplasia - patients with grave systemic diseases as Carcinoma, multiple sclerosis, with strong immunosupressive drug intake or chemotherapy. - congenital coagulation disorders - intake of strong anticoagulants like warfarin a.o. ( chinese herbal remedies can interact in some cases) - diagnosis of a grave psychiatric disease with intake of neuroleptics or lithium, and the necessity of regular psychiatric care. - GI bleeding during the last 8 weeks before begin of trial ( with the exception of mild hemorrhoidal bleeding) - chronic anemia ( hemoglobin < 12 in women, < 13 in men) - chronic alcoholics - pathological liver and kidney labarotory parameters - liver and kidney disease in pat. history - IDDM or NIDDM, if HbA1c > 8 - Body -mass index > 30 - pregnancy, nursing; before admission to trial fertile women are obligated to a pregnancy test and a gynacologal examination; this has to be repeated once per month till the end of the trial. An effective contraception has to take place. - known allergies against any plant, which is used - if negative compliance is to be expected. - if there is considerable experience with chinese medicinal drugs |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Global WOMAC Score (Western Ontario and McMasters University) after 18 Weeks. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
use of herbal remedies according to diagnosis of traditional chinese medicine |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
A 12 month period is reckoned for intervention and evaluation(=last visit of the last trial subject after maximum of 12 months) Another 12 months for utilizing the accomplished data. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 24 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 24 |